ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Piramal Pharma Solutions plans to spend $61 million to expand its antibody-drug conjugate (ADC) facility in Grangemouth, Scotland. The drug services company says the project will begin with the addition of two ADC production suites next year. A sterile fill-and-finish facility and two additional large-scale production suites are planned. The company is also investing $14 million in equipment, infrastructure, and utility improvements at its active pharmaceutical ingredient plant in Morpeth, England.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X